CST, 3696S, DR5 Antibody

Polyclonal Antibody for studying TRAIL-R2/DR5. Validated for Western Blotting. Highly specific and rigorously validated in-house, DR5 Antibody (CST #3696) is ready to ship. Product Usage Information Western Blotting: 1:1000 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting Specificity / Sensitivity DR5 Antibody detects the precursor and mature forms of isoforms 1 and 2 of DR5. Cross reactivity was not detected with other family members. Species Reactivity: Human Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding cysteine 248 of isoform 1 of human DR5. Antibodies were purified by protein A and peptide affinity chromatography. Background The tumor necrosis factor receptor family, which includes TNF-RI, Fas, DR3, DR4, DR5, and DR6, plays an important role in the regulation of apoptosis in various physiological systems (1,2). The receptors are activated by a family of cytokines that include TNF, FasL, and TNF-related apoptosis-inducing ligand (TRAIL). They are characterized by a highly conserved extracellular region containing cysteine-rich repeats and a conserved intracellular region of about 80 amino acids termed the death domain (DD). The DD is important for transducing the death signal by recruiting other DD containing adaptor proteins (FADD, TRADD, RIP) to the death-inducing signaling complex (DISC), resulting in activation of caspases. DR5 is a receptor for TNF-related apoptosis inducing ligand (TRAIL), which has been been shown to induce apoptosis in variety of cell types and has been targeted for cancer therapy (1-5). Structurally, DR5 contains an amino-terminal leader cleavage site followed by an extracellular region containing two cysteine-rich repeats, then a central transmembrane domain and a carboxy-terminal death domain. DR5 is expressed in a wide variety of tissues and is transcriptional target for p53 (6-8). It induces apoptosis through a FADD-dependent pathway. Deletion of DR5 leads to resistance in TRAIL-mediated apoptosis as well as an abrogated response to DNA-damaging stimuli (9). Alternate Names apoptosis inducing protein TRICK2A/2B; apoptosis inducing receptor TRAIL-R2; CD262; cytotoxic TRAIL receptor-2; death domain containing receptor for TRAIL/Apo-2L; death receptor 5; DR5; Fas-like protein; KILLER; KILLER/DR5; p53-regulated DNA damage-inducible cell death receptor(killer); TNF receptor superfamily member 10b; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TR10B; TRAIL receptor 2; TRAIL-R2; TRAILR2; TRICK2; TRICK2A; TRICK2B; TRICKB; Tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; ZTNFR9 Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 40, 48 SOURCE: Rabbit